Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030022090> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2030022090 endingPage "A107" @default.
- W2030022090 startingPage "A107" @default.
- W2030022090 abstract "• Prasugrel was initially selected in 26% of patients at the time of PCI • The strongest predictors of prasugrel use included cardiogenic shock (OR 1.68), DES use (OR 1.45), and younger age (OR 1.36) • Prasugrel use was highest in patients at low mortality/ low bleeding risk (31.8%). We observed modestly but paradoxically higher prasugrel use in patients at low mortality/high bleeding risk (26.2%) than those at high mortality/low bleeding risk (24.1%) • Unadjusted rates of MACE were lower in prasugrel vs. clopidogrel-treated patients in all risk groups. After multivariable adjustment, use of prasugrel compared with clopidogrel in patients with high predicted bleeding was associated with higher rates of bleeding and MACE RELEVANT DISCLOSURE INFORMATION: The following relationships exist related to this presentation: AN Vora: NIH T-32 training grant #5 T32 HL 7101-38; ED Peterson: full disclosures listed at www.dcri.org; LA McCoy: no disclosures; MB Effron: employee of Lilly (shareholder/options); K Anstrom: research support from AstraZeneca, Eli Lilly & Company, Medtronic, and Proctor and Gamble; has served as a consultant for Abbott Vascular, AstraZeneca, Bristol Myers Squibb, and Ikaria; and has served on Data Monitoring Committees for Pfizer and Vertex; DE Faries: employee of Lilly (shareholder/options); ME Zettler: employee of Lilly (shareholder/options): GC Fonarow: Amgen, Bayer,Boston Scientific, Johnson & Johnson, Medicines Company, Medtronic, Novartis,Takeda, Gambro, Novartis; BA Baker: employee of Daiichi Sankyo (shareholder/options); GW Stone: Guided Delivery Systems, Miracor, Reva, Arstasis, Biostar family funds, Caliber, Medfocus family funds, micardia, VNT, TherOx; TY Wang: research support from Eli Lilly, Daiichi Sankyo, Astra Zeneca, Gilead, Glaxo Smith Kline, Boston Scientific and Regeneron. Methods" @default.
- W2030022090 created "2016-06-24" @default.
- W2030022090 creator A5030940497 @default.
- W2030022090 creator A5042045701 @default.
- W2030022090 creator A5046629853 @default.
- W2030022090 creator A5070062505 @default.
- W2030022090 creator A5070178181 @default.
- W2030022090 creator A5070928171 @default.
- W2030022090 creator A5071968251 @default.
- W2030022090 creator A5077882567 @default.
- W2030022090 creator A5080570079 @default.
- W2030022090 creator A5081220515 @default.
- W2030022090 creator A5085434047 @default.
- W2030022090 date "2015-03-01" @default.
- W2030022090 modified "2023-09-24" @default.
- W2030022090 title "SELECTION OF PRASUGREL VERSUS CLOPIDOGREL AMONG MYOCARDIAL INFARCTION PATIENTS WITH HIGH VERSUS LOW PREDICTED MORTALITY AND BLEEDING RISKS: INSIGHTS FROM TRANSLATE-ACS" @default.
- W2030022090 doi "https://doi.org/10.1016/s0735-1097(15)60107-3" @default.
- W2030022090 hasPublicationYear "2015" @default.
- W2030022090 type Work @default.
- W2030022090 sameAs 2030022090 @default.
- W2030022090 citedByCount "0" @default.
- W2030022090 crossrefType "journal-article" @default.
- W2030022090 hasAuthorship W2030022090A5030940497 @default.
- W2030022090 hasAuthorship W2030022090A5042045701 @default.
- W2030022090 hasAuthorship W2030022090A5046629853 @default.
- W2030022090 hasAuthorship W2030022090A5070062505 @default.
- W2030022090 hasAuthorship W2030022090A5070178181 @default.
- W2030022090 hasAuthorship W2030022090A5070928171 @default.
- W2030022090 hasAuthorship W2030022090A5071968251 @default.
- W2030022090 hasAuthorship W2030022090A5077882567 @default.
- W2030022090 hasAuthorship W2030022090A5080570079 @default.
- W2030022090 hasAuthorship W2030022090A5081220515 @default.
- W2030022090 hasAuthorship W2030022090A5085434047 @default.
- W2030022090 hasConcept C126322002 @default.
- W2030022090 hasConcept C164705383 @default.
- W2030022090 hasConcept C2777028646 @default.
- W2030022090 hasConcept C2777849778 @default.
- W2030022090 hasConcept C500558357 @default.
- W2030022090 hasConcept C71924100 @default.
- W2030022090 hasConceptScore W2030022090C126322002 @default.
- W2030022090 hasConceptScore W2030022090C164705383 @default.
- W2030022090 hasConceptScore W2030022090C2777028646 @default.
- W2030022090 hasConceptScore W2030022090C2777849778 @default.
- W2030022090 hasConceptScore W2030022090C500558357 @default.
- W2030022090 hasConceptScore W2030022090C71924100 @default.
- W2030022090 hasIssue "10" @default.
- W2030022090 hasLocation W20300220901 @default.
- W2030022090 hasOpenAccess W2030022090 @default.
- W2030022090 hasPrimaryLocation W20300220901 @default.
- W2030022090 hasRelatedWork W14452866 @default.
- W2030022090 hasRelatedWork W2005486302 @default.
- W2030022090 hasRelatedWork W2049397185 @default.
- W2030022090 hasRelatedWork W2399063111 @default.
- W2030022090 hasRelatedWork W2775269597 @default.
- W2030022090 hasRelatedWork W2796947617 @default.
- W2030022090 hasRelatedWork W2952399767 @default.
- W2030022090 hasRelatedWork W2979889017 @default.
- W2030022090 hasRelatedWork W3134665543 @default.
- W2030022090 hasRelatedWork W3136991612 @default.
- W2030022090 hasVolume "65" @default.
- W2030022090 isParatext "false" @default.
- W2030022090 isRetracted "false" @default.
- W2030022090 magId "2030022090" @default.
- W2030022090 workType "article" @default.